Across TCGA pan-cancer cohorts, MRPL50P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MRPL50P2’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where MRPL50P2 RNA is repressed in tumor relative to normal tissue. In most cancer types MRPL50P2 is over-expressed in tumor, although a few such as THCA and STAD show the opposite, repressed pattern.
THCA and STAD are the cancer types where MRPL50P2 tumor–normal differential expression is most reproducible.